NeuroMetrix is a publicly traded (Nasdaq: NURO) medical device company located in Waltham, Massachusetts. The Company was founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology, and has been public since 2004.
The Company invented the concept of point-of-care neurodiagnostic testing and built this market over the past 15 years. The Company currently develops and markets home use and point-of-care devices for the treatment and management of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and managed care organizations to optimize patient care and reduce healthcare costs.
The company markets the NC-stat® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company also markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company has additional therapeutic products in its pipeline.